Plain-English translation of NCT04134559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether a medication called can help young patients whose liver cancer has come back or is no longer responding to previous treatments. works by helping your body's immune system recognize and fight cancer cells. While it hasn't been approved specifically for pediatric liver cancer, researchers want to see if it could be an effective option for young patients in this situation.
Liver cancer in children is rare but serious, and when it returns or becomes resistant to standard treatments, options are limited. This medication has shown promise in other cancers by boosting the immune system, and researchers want to understand whether it can work similarly for young people with liver cancer, and which patients are most likely to benefit.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the medication by infusion every 3 weeks. Each 3-week period is called a treatment cycle. Your doctor will monitor your health closely with blood tests and imaging scans to see how you're responding to the treatment and to watch for any side effects. The study will also collect biological samples to help researchers understand which patients benefit most from this approach.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States